SPA
PRLD icon

Sherbrooke Park Advisers’s Prelude Therapeutics PRLD Stock Holding History

Sherbrooke Park Advisers’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,048
Closed -$41.5K – 1077
2024
Q3 		$41.5K Buy
+20,048
New +$92.8K 0.01% 870

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Sherbrooke Park Advisers's PRLD Position: Q4 2024 in Review

Sherbrooke Park Advisers sold out of Prelude Therapeutics (PRLD) in Q4 2024, closing a stake of 20,048 shares — an estimated $41.5K sold.

Sherbrooke Park Advisers first reported a position in PRLD in Q3 2024 and held it in 1 quarter. The position peaked at $41.5K in Q3 2024. 62 funds tracked by Wall St. Rank hold PRLD as of Q4 2024.

  • Sherbrooke Park Advisers reported no remaining Prelude Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 20,048 Prelude Therapeutics shares in Q4 2024, an estimated $41.5K.
  • Sherbrooke Park Advisers first reported a position in Prelude Therapeutics in Q3 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Prelude Therapeutics position peaked at $41.5K in Q3 2024.
  • 62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.